Salud financiera de hoja de balance de Alzamend Neuro

Salud financiera controles de criterios 2/6

Alzamend Neuro tiene un patrimonio de los accionistas total de $-3.8M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $782.6K y $4.6M respectivamente.

Información clave

-11.6%

Ratio deuda-patrimonio

US$300.71k

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$376.05k
Patrimonio	-US$2.59m
Total pasivo	US$3.23m
Activos totales	US$631.59k

Actualizaciones recientes sobre salud financiera

Recent updates

Alzamend stock falls amid start of AL001 dosing in healthy people in Alzheimer's trial

Oct 05

Alzamend seeks FDA nod for early-stage trial of its therapy for Alzheimer’s type dementia

Sep 29

Alzamend Neuro receives positive pre-IND response from FDA for AL001

Jul 18

Alzamend: Biotech To Watch With 2 Drugs Targeting Multi-Billion Dollar Alzheimer's Market

Dec 18

Alzamend Neuro closes $14.4M IPO

Jun 17

Análisis de la situación financiera

Pasivos a corto plazo: ALZN tiene patrimonio neto negativo. Es una situación más grave que activos a corto plazo que no cubren pasivos a corto plazo.

Pasivo a largo plazo: ALZN tiene patrimonio neto negativo. Esta situación es más grave que el hecho de que los activos a corto plazo no cubran los pasivos a largo plazo.

Historial y análisis de deuda-patrimonio

Nivel de deuda: ALZN tiene patrimonio negativo, una situación más grave que un alto nivel de endeudamiento.

Reducción de la deuda: ALZN tiene patrimonio neto negativo, por lo que no necesitamos comprobar si su deuda se ha reducido con el tiempo.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: ALZN tiene suficiente cash runway para 0 meses según el flujo de caja libre último declarado, pero desde entonces ha obtenido capital adicional.

Pronóstico de cash runway: Se prevé que ALZN disponga de suficiente cash runway para 0 meses según las estimaciones de flujo de caja libre, aunque ha obtenido desde entonces capital adicional.

Salud financiera de hoja de balance de Alzamend Neuro

Salud financiera controles de criterios 2/6

Información clave

Actualizaciones recientes sobre salud financiera

Alzamend Neuro, Inc. announced delayed annual 10-K filing

Alzamend Neuro Regains Compliance with Nasdaq's Minimum Bid Price Requirement

The Nasdaq Stock Market LLC Determines Alzamend Neuro's Common Stock to be Scheduled for Delisting from The Nasdaq Capital Market and to be Suspended at the Opening of Business on April 4, 2024

The Nasdaq Stock Market LLC Determines Alzamend Neuro's Common Stock to be Scheduled for Delisting from The Nasdaq Capital Market and to be Suspended at the Opening of Business on April 4, 2024

Alzamend Neuro, Inc. announced delayed 10-Q filing

Alzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price Requirement

Recent updates

Alzamend Neuro, Inc. announced delayed annual 10-K filing

Alzamend Neuro Regains Compliance with Nasdaq's Minimum Bid Price Requirement

Alzamend Neuro, Inc. announced that it expects to receive $25 million in funding

Alzamend Neuro, Inc. has completed a Follow-on Equity Offering in the amount of $1.3 million.

Alzamend Neuro, Inc., Annual General Meeting, May 13, 2024

The Nasdaq Stock Market LLC Determines Alzamend Neuro's Common Stock to be Scheduled for Delisting from The Nasdaq Capital Market and to be Suspended at the Opening of Business on April 4, 2024

The Nasdaq Stock Market LLC Determines Alzamend Neuro's Common Stock to be Scheduled for Delisting from The Nasdaq Capital Market and to be Suspended at the Opening of Business on April 4, 2024

Alzamend Neuro, Inc., Annual General Meeting, Apr 30, 2024

Alzamend Neuro, Inc. announced delayed 10-Q filing

Alzamend Neuro, Inc. Appoints Milton C. Ault, III as a Director and Vice Chairman

Price target decreased by 67% to US$20.00

New major risk - Revenue and earnings growth

Alzamend Neuro, Inc. Receives FDA " Study May Proceed" Notification for A Phase IIA Clinical Trial of Al001, A Next-Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder Patients

Alzamend Neuro Receives FDA " Study May Proceed" Notification for A Phase IIA Clinical Trial of Al001, A Next-Generation Lithium Therapeutic Drug Candidate, in Major Depressive Disorder Patients

Alzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price Requirement

Alzamend Neuro, Inc. Submits IND Application for A Phase IIa Clinical Trial in Post-Traumatic Stress Disorder Patients of Next-Generation Lithium Therapeutic Drug Candidate AL001

New major risk - Market cap size

New major risk - Share price stability

Alzamend Neuro, Inc. Submits Investigational New Drug Application for A Phase IIA Clinical Trial in Major Depressive Disorder Patients of Its Next-Generation Lithium Therapeutic Drug Candidate AL001

Price target increased by 58% to US$6.50

Alzamend Neuro, Inc Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients

Alzamend Neuro Receives Non-Compliance Notice From Nasdaq

Alzamend Neuro Receives Extension by Nasdaq Panel to Regain Compliance with the Minimum Bid Price Continued Listing Requirement

New major risk - Negative shareholders equity

Alzamend Neuro Receives Notification from Nasdaq Regarding Not Eligible for Second 180 Day Compliance Period

Is Alzamend Neuro (NASDAQ:ALZN) In A Good Position To Deliver On Growth Plans?

Alzamend N Neuro, Inc. Announces Positive Phase IIA Clinical Trial Results for AL001

Alzamend N Neuro, Inc. Announces Positive Phase IIA Clinical Trial Results for AL001

Price target decreased by 41% to US$4.13

Is Alzamend Neuro (NASDAQ:ALZN) In A Good Position To Deliver On Growth Plans?

Price target decreased to US$7.25

High number of new and inexperienced directors

Price target decreased to US$7.25

Alzamend Neuro, Inc. Receives FDA "Study May Proceed" Letter for Phase I/IIa Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (Alzn002) to Treat Mild to Moderate Dementia of the Alzheimer's Type

We're Not Very Worried About Alzamend Neuro's (NASDAQ:ALZN) Cash Burn Rate

Alzamend Neuro Inc. Announces Addition of Healthy Subjects to Ongoing Phase IIA Clinical Trial for AL001 in Alzheimer’S Subjects

Alzamend stock falls amid start of AL001 dosing in healthy people in Alzheimer's trial

Alzamend Neuro, Inc. Submits Ind Application for Phase I/Iia Trial for an Immunotherapy (Alzn002) to Treat Mild to Moderate Dementia of the Alzheimer's Type

Alzamend seeks FDA nod for early-stage trial of its therapy for Alzheimer’s type dementia

Alzamend Neuro Has Regained Compliance with Nasdaq's Minimum Bid Price Requirement

Price target increased to US$15.00

Alzamend Neuro, Inc. Announces CFO Changes

Alzamend Neuro Receives Positive Pre-Ind Response from Fda for Al001 Treatment of Bipolar Disorder, Major Depressive Disorder and Post-Traumatic Stress Disorder

Alzamend Neuro receives positive pre-IND response from FDA for AL001

Alzamend Neuro Receives Non-Compliance Notice from Nasdaq

Alzamend Neuro Announces Pre-IND Submission for AL001 as a Treatment of Bipolar Disorder, Major Depressive Disorder and Post-Traumatic Stress Disorder

Alzamend Neuro, Inc. Announces Initiation of Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s

No independent directors

Alzamend Neuro, Inc. Announces Appointment of Terri Hunter to Its Scientific Advisory Board

Alzamend Neuro Announces Full Data Set from Phase 1 First-In-Human Clinical Trial for Al001 Treatment of Dementia Related to Alzheimer’S

Alzamend Neuro Announces Positive Topline Data from Phase 1 First-In-Human Clinical Trial for Al001 Treatment of Dementia Related to Alzheimer’s

Alzamend: Biotech To Watch With 2 Drugs Targeting Multi-Billion Dollar Alzheimer's Market

Director recently sold US$57k worth of stock

Alzamend Neuro Announces Date for Delivery of Topline Data for Phase 1 First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimer’s

Alzamend Neuro Announces Initiation of Phase I First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimer’s Disease

Alzamend Neuro Receives Positive Results for Al002 in GLP Toxicology Study Using a Transgenic Mouse Model of Alzheimer’s Disease

Alzamend Neuro Submits IND Application for Al001 for Dementia Related to Alzheimer’s Disease

Alzamend Neuro closes $14.4M IPO

Alzamend Neuro, Inc. has completed an IPO in the amount of $12.5 million.

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera